Drug Profile
Ozoralizumab - Ablynx/Eddingpharm/Taisho Pharmaceutical
Alternative Names: anti-TNFα Nanobody®; ATN-103; Nanozora; Nanozora® 30mg Autoinjector; Ozoralizumab autoinjector; PF-5230896; TS-152Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Ablynx
- Developer Ablynx; Eddingpharm; Pfizer; Taisho Pharmaceutical
- Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies; Proteins
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Rheumatoid arthritis
- Discontinued Ankylosing spondylitis; Crohn's disease; Psoriatic arthritis